SpaceX vs Twist Bioscience Corp — how do they compare? SpaceX trades at $123.46 (market cap $1.58T), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: SpaceX is far larger — about 289.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| SPCX | TWST | |
|---|---|---|
Market Cap | $1.58T | $5.45B |
Sector | Technology | Health |
52-Week High | $202.09 | $102.88 |
52-Week Low | $119.85 | $24.16 |
Enterprise Value | $1.59T | $5.37B |
Signals from Pluang's Aura AI — not financial advice
SPCX trades at $119.85, down 3.34% today and 45% below its post-IPO high, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 EPS of -$1.19, missing estimates by 260%, while revenue grew to $18.67B in 2025. SpaceX faces significant valuation concerns with a P/S of 84 and negative profitability metrics, though analyst consensus remains 100% buy-rated with a $237.78 price target representing 98% upside potential.
The stock presents high-risk/high-reward potential with strong institutional support but faces near-term headwinds from August lockup expirations and persistent losses. Long-term growth depends on Starlink expansion and AI contract wins, though current fundamentals don't justify the premium valuation. Investors must weigh analyst optimism against cash burn and execution risks in the competitive space sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →